Glibenclamide, an oral antihyperglycemic agent for treating type 2 diabetes, was first discovered in 1969 and approved in the U.S. in 1984. Due to side effects and competition from other sulfonylureas, its market presence has sharply declined, with a notable reduction in prescriptions in recent years. The project report aims to analyze the prescribing patterns and brand preferences among doctors, revealing that the top brand, Daonil, is now prescribed infrequently.

1. Project Report On glibenclamide
SUBMITTED TO :
MR. UBADA AQEEL
SUBMITTED BY :
MD. FAHEEM KHAN
NITESH SHARMA
NITESH SHRIVASTAV
PRAGYA TIWARI
PRAVEEN MISHRA

2.  Glibenclamide or glyburide is an oral antihyperglycemic agent
used for the treatment of non-insulin-dependent diabetes
mellitus (NIDDM)
 It was discovered in 1969 and approved for medical use in the
united states in 1984.
 Sulfonylureas increase both basal insulin secretion and meal-
stimulated insulin release.
Drug Class : Hypoglycemics ;Sulfonylureas
Indications : Diabetes mellitus, type 2
 SIDE EFFECTS : Hypoglycemia, Angioedema, Weight gain etc.

3. The mechanism action of drug
consists in the inhibition of the
ATP sensitive K+ channel which
lead to the depolarisation of the
cells and insulin secretion.

4. The primary objective of this project is :
* To find knowledge for the different top brands of
GLIBENCLAMIDE.
* To know about the number of prescriptions per week.
* Doctors who prescribed it.
* Reason for prescribing the drug of particular brand.

5.  Glibenclamide is the research molecule of Boehringer Mannheim (now part of
Roche) and Hoechst (now part of sanofi)
 It is a poor man drug.
 Glibenclamide was once on the top of the ladder for the choice of drug in the
class of sulphonylureas.
 With the time glibenclamide could not compete with the other competitors of
the class sulphonylureas like glimipride, glipizide etc.
 Many popular brands like Daonil which once ruled the market are now rarely
prescribed.
 One of the most potent anti-diabetic drug just ruled out of the market because
of its side effects like hypoglycemia, angioedema, etc.

6. Glibenclamide
Glicazide
Glipizide
Glimipride
Year (2015-2017)
Year ( 2018-2019)
Glimipride
Glipizide
Glicazide
Glibenclamide

7. SR.N
O
BRAND
NAME
COMAPANY COMPOSITION NO.OF PRESCRIPTION/MONTH
1 DAONIL TAB SANOFI GLIBENCLAMIDE 15-20
2 GLINIL TAB CIPLA GLIBENCLAMIDE 14-17
3 EUGLUC-ON ABBOT GLIBENCLAMIDE 10-12
4 DIABETROL ABBOT GLIBENCLAMIDE +
METFORMIN
8-10
5 GLYBORAL USV GLIBENCLAMIDE 5-8
YEAR (2015-2017)

8. YEAR (2018- 2019)
SR.
NO
BRAND NAME COMPANY COMPOSITION NO.OF
PRESCRIPTION/MONTH
1 DAONIL TAB SANOFI GLIBENCLAMIDE 1-2
2 GLINIL TAB CIPLA GLIBENCLAMIDE 0-1
3 EUGLUC-ON ABBOT GLIBENCLAMIDE 0
4 DIABETROL ABBOT GLIBENCLAMIDE +
METFORMIN
1-2
5 GLYBORAL USV GLIBENCLAMIDE 0

9. Source of data collection

10.  Epidermiological suggest that the administration of of
Glibenclamide is associated with an increased risk of
cardivascular mortality,compared to treatment with
Metformin or Gliclazide.
 Cause moderate to severe lowering of blood glucose level.
 Cause mild to moderate weight gain on consumption.
 Cause hemolytic anaemia if one have a rare genetic disorder
called G6PD defficiency.

11.  DR. KRISHNA VISHWAS ( HOD)
ENDROCRIONOLOGY, SAFADARJUNG HOSPITAL
 DR. AJAY KUMAR AJMANI
APOLLO PHARMACY
 DR. AKHILESH KUMAR
BINDA POLYCLINIC

12. * On different brands of Glibenclamide availability across stores in delhi.
* Field work is more effective than theoretical knowledge alone.
* Reinforced with the knowledge that the drug Glibenclamide is prescribed
in least number from last two years.
OBSTACLES
* Rejection from some of the chemist and doctors.
* Due to lack of time doctors and chemist refused to give information.
* Several chemist shop closed for long lunch breaks on working days

13.  Glibenclamide should be used with caution especially in geriatic
population. Specific characteristics, including renal insufficiency
and advancing age may predispose patients to the development
of drug-induced hypoglycaemia. Patient evaluation is critical in
identifying patients at greatest risk and in preventing
complications.
 Top brand of glibenclamide was Daonil M – Glibenclamide and
metformin hydrocholoride, Sanofi Aventis Pharma India
 Total number of prescription per month
was 1 to 2 or nill.
 Reason for prescribing Daonil is that it is
not addictive.